Loading...
GLSI logo

Greenwich LifeSciences, Inc.NasdaqCM:GLSI Stock Report

Market Cap US$286.8m
Share Price
n/a
1Y54.6%
7D-2.9%
1D-2.7%
Portfolio Value
​
View

Greenwich LifeSciences, Inc.

NasdaqCM:GLSI Stock Report

Market Cap: US$286.8m

Greenwich LifeSciences (GLSI) Stock Overview

A clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. More details

GLSI fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Risk Analysis

Has less than 1 year of cash runway

Earnings have declined by 36.5% per year over past 5 years

Makes less than USD$1m in revenue ($0)

Volatile share price over the past 3 months compared to the US market


GLSI Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Top Community Narratives

View all narratives

Greenwich LifeSciences, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Greenwich LifeSciences
Historical stock prices
Current Share PriceUS$19.01
52 Week HighUS$34.10
52 Week LowUS$7.78
Beta1.39
1 Month Change-20.39%
3 Month Change-31.47%
1 Year Change54.55%
3 Year Change108.44%
5 Year Change-56.24%
Change since IPO280.20%

Recent News & Updates

Seeking Alpha • 14h

Greenwich LifeSciences The Overlooked Need

Summary Greenwich LifeSciences is a single-asset biotech focused on GLSI-100, an immunotherapy for HER2-positive breast cancer, currently in Phase 3 trials. GLSI-100 demonstrated a 70-80% reduction in cancer recurrence in Phase 2b, outperforming approved therapies, with no serious adverse events reported. GLSI trades at a ~$279M market cap, below recent M&A comps, despite advanced clinical progress and a large addressable market in HER2/neu-positive breast cancer. Risks include binary dependency on GLSI-100 Phase 3 success and near-term need for additional capital, given limited cash reserves. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • 14h

Greenwich LifeSciences The Overlooked Need

Summary Greenwich LifeSciences is a single-asset biotech focused on GLSI-100, an immunotherapy for HER2-positive breast cancer, currently in Phase 3 trials. GLSI-100 demonstrated a 70-80% reduction in cancer recurrence in Phase 2b, outperforming approved therapies, with no serious adverse events reported. GLSI trades at a ~$279M market cap, below recent M&A comps, despite advanced clinical progress and a large addressable market in HER2/neu-positive breast cancer. Risks include binary dependency on GLSI-100 Phase 3 success and near-term need for additional capital, given limited cash reserves. Read the full article on Seeking Alpha
New Narrative • Mar 18

Greenwich LifeSciences will eye a valued future at $460 a share, with GP2 leading the way.

SUMMARY:
Analysis Article • Aug 22

We Think Greenwich LifeSciences (NASDAQ:GLSI) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Jun 26

Greenwich LifeSciences: Trying To Move A Needle That Doesn't Like To Budge

Summary Greenwich LifeSciences, Inc. is a late-stage biotech company focusing on developing an immunotherapy treatment for breast cancer. Their pipeline includes one drug, GLSI-100, currently in a phase 3 trial targeting breast cancer recurrence after surgery. Financially, Greenwich LifeSciences has limited resources with a cash runway of approximately 2 quarters, making it a high-risk investment. Read the full article on Seeking Alpha
Analysis Article • Jan 12

Here's Why We're Not Too Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jan 29

We're Not Very Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 06

Greenwich LifeSciences: Persevering CEO And Interesting Data

Summary Greenwich LifeSciences, Inc. is a one-man, one-asset shop. The asset, GP2, has produced excellent breast cancer data. Greenwich LifeSciences' CEO, Snehal Patel, runs this company almost all by himself. Greenwich LifeSciences, Inc. (GLSI) is a developer of cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. A 2-year IPO with a 2 decades history, GLSI had been lagging over an FDA clinical hold that was placed on its Phase III clinical trial, FLAMINGO-01, citing manufacturing and pharmacy process issues. The stock seems to have stabilized after that, however, at $8 today, it is still nowhere near its 52-week high of $48. GLSI's lead product candidate is GLSI-100, which is a combination of GP2 and GM-CSF. GP2 is a "9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers." This is developed at GLSI. To this is added a GM-CSF, or a recombinant human granulocyte macrophage colony-stimulating factor (sargramostim, Leukine®), a well-known, previously approved molecule. The company is currently running a phase 3 trial led by Baylor and a ​"consortium of prominent cancer centers." A phase 2b trial led by MD Anderson produced solid data. Data was: 0% recurrences over median 5 years follow-up, if fully immunized, versus 11% placebo recurrence rate in 96 patients (p = 0.0338), peak immunity after 6 months, minimal to no side effects, no SAEs attributable to GP2 These patients were on a previous treatment with Herceptin or Kadcyla. The data here not only demonstrates GP2's excellent profile, it also shows that the two other legacy treatments are also highly effective in this population. The opportunity, therefore, lies in those 50% of recurring disease patients who do not respond to these standards of care. As the company says: Following breast cancer surgery, HER2/neu 3+ patients receive Herceptin in the first year and then hope that their breast cancer will not recur, with the odds of recurrence slowly decreasing over the first 5 years. Herceptin reduces recurrence rates from 25% to 12%. GP2 & GM-CSF starting in Year 2 act synergistically with Herceptin to prevent cancer recurrences, if fully immunized, reducing recurrence rates from 11% to 0% at median 5 years follow-up (p = 0.0338), with minimal to no side effects & no SAEs. This synergistic treatment effect could save 1500 to 2000 patients per year from the 17000 patients that could be treated under GLSI-100's initial indication alone.
Seeking Alpha • Jul 11

Greenwich LifeSciences halts stock buyback program

Greenwich LifeSciences (NASDAQ:GLSI) said Monday it suspended its share repurchase program. GLSI repurchased ~520K shares for ~$7.5M under the program, which had been resumed in May. The firm had ~12.8M shares outstanding following the buybacks.
Seeking Alpha • May 19

Greenwich LifeSciences: A First Look

Shares of Greenwich LifeSciences, Inc. are trading near their lowest levels since the stock exploded upward in December 2020 in what was an illustrative example of an inefficient market. A still-pending Phase 3 study launch for its only asset in the treatment of breast cancer that was originally expected to initiate in 2020 is primarily to blame. With 100% disease free survival ("DFS") in a Phase 2b study that concluded in 2018, the recent insider buying merited closer examination. A full investment analysis follows in the paragraphs below.
Seeking Alpha • Apr 21

Greenwich LifeSciences: Insider Buying And Buybacks Telegraph This Company's Vast Potential

Greenwich LifeSciences is a stock relatively new to the market and lesser-known, as it became public in September of 2020. Not long after, the stock skyrocketed over 1000% on early data that the company's GP2 treatment reduced breast cancer recurrences to zero. While this is still a developing story, the company has a Phase III trial dead ahead, which could usher in a new wave of investors. Greenwich LifeSciences stock has pulled back almost 60% since last April, which may present buying opportunity for investors with a long-term mindset. Insiders have been buying, and with the extension of the lockup period and announcement of a share repurchase program, management seems to be telegraphing big things ahead.
Analysis Article • Feb 01

Companies Like Greenwich LifeSciences (NASDAQ:GLSI) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Sep 30

We Think Greenwich LifeSciences (NASDAQ:GLSI) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

GLSIUS BiotechsUS Market
7D-2.9%-3.5%0.8%
1Y54.6%32.8%20.5%

Return vs Industry: GLSI exceeded the US Biotechs industry which returned 32.8% over the past year.

Return vs Market: GLSI exceeded the US Market which returned 20.5% over the past year.

Price Volatility

Is GLSI's price volatile compared to industry and market?
GLSI volatility
GLSI Average Weekly Movement13.1%
Biotechs Industry Average Movement10.2%
Market Average Movement7.2%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.2%

Stable Share Price: GLSI's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: GLSI's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
20066Snehal Patelgreenwichlifesciences.com

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients.

Greenwich LifeSciences, Inc. Fundamentals Summary

How do Greenwich LifeSciences's earnings and revenue compare to its market cap?
GLSI fundamental statistics
Market capUS$286.81m
Earnings (TTM)-US$22.27m
Revenue (TTM)n/a
0.0x
P/S Ratio
-12.5x
P/E Ratio

Is GLSI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GLSI income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$22.27m
Earnings-US$22.27m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-1.52
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did GLSI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/16 21:56
End of Day Share Price 2026/07/16 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Greenwich LifeSciences, Inc. is covered by 1 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert LeBoyerNOBLE Capital Markets, Inc.